Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iRay GroupSHSE:688301 -2.07%95 Receivables Turnover is 1.07 as of Jun. 2026. GuruFocus rates SHSE:688301 with a GF Score™ of 95/100 and a GF Value™ of ¥109.99 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 810 Medical Devices & Instruments companies, iRay Group ranks worse than 80.62% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. iRay Group's Revenue for the
three
months ended in Jun. 2026 was ¥985 Mil. iRay Group's average Accounts Receivable for the
three
months ended in Jun. 2026 was ¥924 Mil.
Hence, iRay Group's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.07.
iRay Group (SHSE:688301) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
iRay Group Receivables Turnover Related Terms
iRay Group Receivables Turnover Historical Data
* Premium members only.
The historical data trend for iRay Group's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688301 vs ISRG, BDX, RMD: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, iRay Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRay Group Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRay Group's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where iRay Group's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iRay Group (SHSE:688301) has a Receivables Turnover of 1.07 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on iRay Group and its competitors. According to the industry distribution chart, iRay Group ranks #653 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 80.6%.
Is iRay Group's Receivables Turnover too high?
iRay Group's current Receivables Turnover is 1.07. The Medical Devices & Instruments industry median Receivables Turnover is 5.62. iRay Group's value of 1.07 is 80.9% below this industry median. Based on the distribution chart, iRay Group ranks #653 out of 810 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, iRay Group has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iRay Group's Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, iRay Group ranks #653 out of 810 companies for Receivables Turnover. This places iRay Group in the lower half of its industry. The industry median Receivables Turnover is 5.62. iRay Group's value of 1.07 is 80.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.62, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iRay Group's current Receivables Turnover of 1.07 is 80.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on iRay Group and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iRay Group's current Receivables Turnover is 1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRay Group stock overvalued right now?
Based on GuruFocus' analysis, iRay Group (SHSE:688301) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥109.99, compared to a current price of ¥88.54 — trading 19.5% below its estimated fair value. The current Receivables Turnover is 1.07 and 80.9% below the Medical Devices & Instruments industry median of 5.62. iRay Group's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For iRay Group (SHSE:688301), the current Receivables Turnover is 1.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRay Group (SHSE:688301) Overvalued in 2026?
Based on GuruFocus' analysis, iRay Group stock appears to be undervalued.
The current stock price of ¥88.54 is trading 19.5% below its estimated GF Value™ of ¥109.99.
GuruFocus considers iRay Group to be Modestly Undervalued.
Key valuation signals for SHSE:688301:
Receivables Turnover: 1.07
GF Value™: ¥109.99 vs. price of ¥88.54 (19.5% below fair value)
Industry Position: 80.9% below the Medical Devices & Instruments median (#653 of 810)
No single metric tells the full story. See the SHSE:688301 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688301 has been successfully added to your 
